GPX4 and glutaminase inhibitors can inhibit pyrimidine synthesis and increase ROS levels in VHL-deficient renal carcinoma cells, and the PARP inhibitor olaparib and glutaminase inhibitors can synergistically inhibit the growth of these cells in vivo and in vitro. This evidence concerns the gene VHL and renal carcinoma.